(as of February 2019, subject to changes) 

TUESDAY, APRIL 9th, 2019

 08.30 - 10.00  

Session 9: Sponsored talks, part I:  Novel drugs and devices in development in status epilepticus and acute seizures
Chairs: Daniel Lowenstein, Matthias Koepp

08.30 - 09.00

Management of prolonged seizures and myoclonic status in CLN2 disease: has this changed over time
Nicola Specchio (on behalf of Biomarin Pharmaceuticals, Inc.)

09.00 - 09.30

Staccato Alprazolam for acute treatment of seizures
Jouko Isojarvi (on behalf of Engage Therapeutics, Inc.)

09.30 - 10.00

Brain distribution and SV2A receptor occupancy of Brivaracetam and Levetiracetam - comparative PET studies in rodents, primates and healthy human subjects
Felix Rosenow (on behalf of UCB, S.A.)

10.00 - 10.30 

Coffee break

10:30 - 12:00

Session 9: Sponsored talks, part II:  Novel drugs and devices in development in status epilepticus and acute seizures
Chairs: Daniel Lowenstein, Peter Kaplan

10.30 - 11.00

Non-Convulsive status epilepticus: letting go of old traditions
Josef Parvizi (on behalf of Ceribell Inc.)

11.00 - 11.30

Enabling drug delivery technologies to address unmet needs in epilepsy
Adrian Rabinowicz (on behalf of Neurelis, Inc.)

11.30 - 12.00

Vagus nerve stimulation in super refractory status epilepticus
Kristl Vonck (on behalf of LivaNova, Plc.)

12:00 - 13:00

Lunch & Posters

13.00 - 14.00

Session 10: Novel treatment approaches in status epilepticus
Chairs: Brian Litt, Nadir Bharucha

13.00 - 13.30

Lessons from the Sage trial
Andrew Cole

13.30 - 14.00

Polytherapy for status epilepticus: the proof of the pudding
Claude Wasterlain

14.00 - 14.30

Coffee break

14.30 - 16.30

Session 11: Novel drugs in the treatment of status epilepticus
Chairs: Nicola Specchio, Tobias Loddenkemper

14.30 - 15.00

New treatments of mitochondrial disease and their impact on status epilepticus
Shamima Rahman

15:00 - 15.30

Fenfluramine : a possible treatment for acute repetitive seizures?
Lieven Lagae

15.30 - 16.00

The promise of new valproic acid amide derivatives in status epilepticus
Meir Bialer

16.00 - 16.30

Propofol Prodrug for the treatment of acute repetitive seizures
Mike Rogawski


 14.30 - 16.30


Parallel session: Data blitz - EEG, basic aspects and experimental treatments 

Chairs: Rob Wykes, David Henshall
International Panel: C. Agrawal, Majid Gaffar

16.30 - 17.00

Simon Shorvon, Eugen Trinka, Matthew Walter


End of Colloquium and Farewell reception




Organisation, registration, abstract submission

PCO Tyrol Congress
Ms. Ina Kaehler
Rennweg 3, 6020 Innsbruck
T: +43-(0)512-57 56 00
F: +43-(0)512-57 56 07


Exhibition and sponsorship

S12! studio 12 GmbH
Kaiser Josef Straße 9
6020 Innsbruck
T: +43-(0)512-890438
F: +43-(0)512-890438-15

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.